Ibusal

Ibusal may be available in the countries listed below.

Ingredient matches for Ibusal

Ibuprofen

Ibuprofen is reported as an ingredient of Ibusal in the following countries:

• Bahrain


• Finland

International Drug Name Search

Vitelle Irospan

Pronunciation: FER-us SUL-fate
Generic Name: Ferrous Sulfate/Vitamin C
Brand Name: Vitelle Irospan

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than 6 years old. Keep this product out of the reach of children. In case of accidental overdose, call a doctor or poison control center right away.

Vitelle Irospan is used for:

Preventing or treating low levels of iron in the blood. It also may be used for other conditions as determined by your doctor.

Vitelle Irospan is a vitamin and mineral combination. It works by replacing iron in your body if your body does not produce enough on its own. The vitamin C helps improve the absorption of iron in the stomach.

Do NOT use Vitelle Irospan if:

• you are allergic to any ingredient in Vitelle Irospan


• you have high levels of iron in your blood

Contact your doctor or health care provider right away if any of these apply to you.

Before using Vitelle Irospan:

Some medical conditions may interact with Vitelle Irospan. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have inflammation of the intestines, Crohn disease, digestive problems, ulcers, anemia, or a blood disease (eg, porphyria, thalassemia)


• if you have had multiple blood transfusions


• if you have sickle cell disease or glucose-6-phosphate dehydrogenase (G6PD) deficiency

Some MEDICINES MAY INTERACT with Vitelle Irospan. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Doxycycline, mycophenolate, penicillamine, or thyroid hormones (eg, levothyroxine) because their effectiveness may be decreased by Vitelle Irospan

This may not be a complete list of all interactions that may occur. Ask your health care provider if Vitelle Irospan may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Vitelle Irospan:

Use Vitelle Irospan as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Vitelle Irospan by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• Swallow Vitelle Irospan whole. Do not break, crush, or chew before swallowing.


• Take Vitelle Irospan with a full glass of water (8 oz/240 mL). Do not lie down for 30 minutes after taking Vitelle Irospan.


• If you are also taking antacids, a bisphosphonate (eg, alendronate), cephalosporin (eg, cephalexin), methyldopa, penicillamine, quinolone (eg, ciprofloxacin), or tetracycline (eg, minocycline) along with Vitelle Irospan, you may need to space the doses several hours apart. Ask your doctor or pharmacist how much time is needed between doses of Vitelle Irospan and your other medicines.


• Certain foods and drinks may decrease the amount of Vitelle Irospan that works in your body. Ask your doctor or pharmacist how you should take Vitelle Irospan if you consume whole grain breads or cereal, dairy products, coffee, or tea.


• If you miss a dose of Vitelle Irospan, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Vitelle Irospan.

Important safety information:

• Do not take large doses of vitamins while you use Vitelle Irospan unless your doctor tells you to.


• Do NOT take more than the recommended dose or take for longer than 6 months without checking with your doctor.


• Vitelle Irospan has iron in it. Iron overdose is a leading cause of fatal poisoning in children younger than 6 years old. In case of an overdose, call a doctor or poison control center right away.


• Diabetes patients - Vitelle Irospan may cause the results of some tests for urine glucose to be wrong. Ask your doctor before you change your diet or the dose of your diabetes medicine.


• Lab tests, including complete blood cell counts and blood iron levels, may be performed while you use Vitelle Irospan. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Vitelle Irospan should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Vitelle Irospan while you are pregnant. Vitelle Irospan is found in breast milk. If you are or will be breast-feeding while you use Vitelle Irospan, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Vitelle Irospan:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; darkened or green stools; diarrhea; nausea; stomach upset.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); black, tarry stools; blood or streaks of blood in the stool; fever; vomiting with continuing sharp stomach pain.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Vitelle Irospan side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include difficulty breathing; loss of consciousness; seizures; severe nausea; stomach pain; tarry stools; unusual tiredness; vomiting; weak, fast heartbeat.

Proper storage of Vitelle Irospan:

Store Vitelle Irospan at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Vitelle Irospan out of the reach of children and away from pets.

General information:

• If you have any questions about Vitelle Irospan, please talk with your doctor, pharmacist, or other health care provider.


• Vitelle Irospan is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Vitelle Irospan. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Vitelle Irospan resources

• Vitelle Irospan Side Effects (in more detail)
• Vitelle Irospan Use in Pregnancy & Breastfeeding
• Vitelle Irospan Drug Interactions
• Vitelle Irospan Support Group
• 0 Reviews for Vitelle Irospan - Add your own review/rating

Compare Vitelle Irospan with other medications

• Vitamin/Mineral Supplementation and Deficiency

zaleplon

ZAL-e-plon

Commonly used brand name(s)

In the U.S.

• Sonata

Available Dosage Forms:

• Capsule

Therapeutic Class: Nonbarbiturate Hypnotic

Uses For zaleplon

Zaleplon belongs to the group of medicines called central nervous system (CNS) depressants (medicines that make you drowsy or less alert). Zaleplon is used to treat insomnia (trouble sleeping). In general, when sleep medicines are used every night for a long time, they may lose their effectiveness. In most cases, sleep medicines should be used only for short periods of time, such as 1 or 2 days, and generally for no longer than 1 or 2 weeks.

zaleplon is available only with your doctor's prescription.

Before Using zaleplon

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For zaleplon, the following should be considered:

Sleep medicines may cause a special type of memory loss or "amnesia". When this occurs, a person does not remember what has happened during the several hours between use of the medicine and the time when its effects wear off. This is usually not a problem since most people fall asleep after taking the medicine. In most instances, memory problems can be avoided by taking zaleplon only when you are able to get at least 4 hours of sleep before you need to be active again. Be sure to talk to your doctor if you think you are having memory problems.

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to zaleplon or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of zaleplon in the pediatric population. Safety and efficacy have not been established .

Geriatric

Appropriate studies performed to date have not demonstrated geriatrics-specific problems that would limit the usefulness of zaleplon in the elderly. However, confusion and falling are more likely to occur in the elderly, who are usually more sensitive than younger adults to the effects of zolpidem. Elderly patients may require a lower dose to help reduce unwanted effects .

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	C	Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding

Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking zaleplon, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using zaleplon with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Fospropofol


• Hydromorphone


• Oxycodone


• Tapentadol


• Zolpidem

Using zaleplon with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

• Cimetidine


• Rifampin

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using zaleplon with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use zaleplon, or give you special instructions about the use of food, alcohol, or tobacco.

• Ethanol

Other Medical Problems

The presence of other medical problems may affect the use of zaleplon. Make sure you tell your doctor if you have any other medical problems, especially:

• Alcohol abuse (or history of) or


• Drug abuse or dependence (or history of)— Dependence on zaleplon may develop.

• Breathing problems or


• Mental depression—Zaleplon may make the condition worse.

• Liver disease— Higher blood levels of zaleplon may result, increasing the chance of side effects.

Proper Use of zaleplon

Take zaleplon only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. If too much is taken, it may become habit-forming (causing mental or physical dependence).

Take zaleplon just before going to bed, when you are ready to go to sleep. zaleplon works very quickly to put you to sleep.

Do not take zaleplon when your schedule does not permit you to get at least 4 hours of sleep.If you must wake up before this, you may continue to feel drowsy and may experience memory problems, because the effects of the medicine have not had time to wear off.

Zaleplon may be taken with or without food or on a full or empty stomach. However, taking zaleplon with or immediately after a heavy or a high fat meal may make zaleplon not work as fast.

zaleplon should come with a Medication Guide. Read and follow these instructions carefully. Ask your doctor if you have any questions .

Dosing

The dose of zaleplon will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of zaleplon. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (capsules):
  
  • For the treatment of insomnia (trouble in sleeping):
    
    • Adults—10 milligrams (mg) once a day at bedtime
    
    
    • Older adults—5 mg once a day at bedtime
    
    
    • Children up to 18 years of age—Use and dose must be determined by doctor.
    
    
  
  

Missed Dose

If you miss a dose of zaleplon, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using zaleplon

It is very important that your doctor check your progress at regular visits to make sure zaleplon is working properly and to check for unwanted effects .

If you think you need to take zaleplon for more than 7 to 10 days, be sure to discuss it with your doctor. Insomnia that lasts longer than this may be a sign of another medical problem.

zaleplon will add to the effects of alcohol and other central nervous system (CNS) depressants (medicines that cause drowsiness). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies or colds: sedatives, tranquilizers, or sleeping medicines; prescription pain medicine or narcotics; barbiturates; medicine for seizures; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are using zaleplon.

zaleplon may cause some people, especially older persons, to become drowsy, dizzy, lightheaded, clumsy or unsteady, or less alert than they are normally. Even though zaleplon is taken at bedtime, it may cause some people to feel drowsy or less alert on arising. Make sure you know how you react to zaleplon before you drive, use machines, or do anything else that could be dangerous if you are dizzy, unsteady, or are not alert or able to see well.

If you develop any unusual and strange thoughts or behavior while taking zaleplon, be sure to discuss it with your doctor. Some changes that have occurred in people taking zaleplon are like those seen in people who drink alcohol and then act in a manner that is not normal. Other changes may be more unusual and extreme, such as confusion, hallucinations (seeing, hearing, smelling, or feeling things that are not there), and unusual excitement, nervousness, or irritability.

zaleplon may cause sleep-related behaviors such as driving a car (sleep-driving), walking (sleep-walking), having sex, making phone calls, or preparing and eating food while asleep or not fully awake. If these reactions occur, tell your doctor right away .

If you will be taking zaleplon for a long time, do not stop taking it without first checking with your doctor. Your doctor may want you to reduce gradually the amount you are taking before stopping completely. Stopping zaleplon suddenly may cause withdrawal side effects.

After taking zaleplon for insomnia, you may have difficulty sleeping (rebound insomnia) for the first few nights after you stop taking it.

If you think you or someone else may have taken an overdose of zaleplon, get emergency help at once. Taking an overdose of zaleplon or taking alcohol or other CNS depressants with zaleplon may lead to breathing problems and unconsciousness. Some signs of an overdose are clumsiness or unsteadiness, confusion, severe drowsiness, low blood pressure, unusual dullness or feeling sluggish, and troubled breathing.

Zaleplon may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Stop taking zaleplon and call your doctor right away if you have itching, hives, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth while you are using zaleplon .

zaleplon Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Less common

• Anxiety


• blurred or double vision


• not feeling like oneself

Rare

• Nosebleed


• seeing, hearing, smelling, or feeling things that are not there

Get emergency help immediately if any of the following symptoms of overdose occur:

Symptoms of overdose

• Confusion


• clumsiness or unsteadiness, severe


• dizziness or fainting


• drowsiness, severe


• weak muscle tone


• troubled breathing


• unusual dullness or feeling sluggish

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Dizziness


• headache


• muscle pain


• nausea

Less common

• Abdominal pain


• burning, prickling, or tingling sensation


• constipation


• cough


• difficulty concentrating


• drowsiness


• dryness of mouth


• excess muscle tone


• eye pain


• fever


• heartburn, indigestion, or acid stomach


• itching


• itching or burning eyes


• joint stiffness and/or pain


• memory loss


• menstrual pain


• mental depression


• nervousness


• sensitive hearing


• severe headache


• shortness of breath


• skin rash


• tightness in chest


• trembling or shaking


• troubled breathing


• unusual weakness or tiredness


• wheezing

After you stop using zaleplon, it may still produce some side effects that need attention. During this period of time, check with your doctor immediately if you notice the following side effects:

• Abdominal and muscle cramps


• convulsions (seizures)


• increased sweating


• sadness


• trembling or shaking


• vomiting

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: zaleplon side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More zaleplon resources

• Zaleplon Side Effects (in more detail)
• Zaleplon Dosage
• Zaleplon Use in Pregnancy & Breastfeeding
• Drug Images
• Zaleplon Drug Interactions
• Zaleplon Support Group
• 17 Reviews for Zaleplon - Add your own review/rating

• Zaleplon Prescribing Information (FDA)


• Zaleplon Professional Patient Advice (Wolters Kluwer)


• Zaleplon Monograph (AHFS DI)


• Zaleplon MedFacts Consumer Leaflet (Wolters Kluwer)


• Sonata Prescribing Information (FDA)


• Sonata Consumer Overview

Compare zaleplon with other medications

• Insomnia

Cyclocort

Generic Name: amcinonide topical (am SIN oh nide)

Brand Names: Cyclocort

What is Cyclocort (amcinonide topical)?

Amcinonide is a topical (for the skin) steroid. It reduces the actions of chemicals in the body that cause inflammation, redness, and swelling.

Amcinonide topical is used to treat the inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.

Amcinonide topical may also be used for other purposes not listed in this medication guide.

What is the most important information I should know about Cyclocort (amcinonide topical)?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with amcinonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period. Contact your doctor if your condition does not improve within 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection.

What should I discuss with my healthcare provider before using Cyclocort (amcinonide topical)?

Do not use this medication if you are allergic to amcinonide.

Before using amcinonide topical, tell your doctor if you are allergic to any drugs, or if you have any type of skin infection.

Also tell your doctor if you have diabetes. Topical steroid medicines absorbed through the skin may increase the glucose (sugar) levels in your blood or urine.

FDA pregnancy category C. This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether amcinonide topical passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Do not use this medication on a child without a doctor's advice. Children are more likely to absorb large amounts of a topical steroid through the skin. Steroid absorption in children may cause unwanted side effects, or a delay in growth with long-term use. Talk with your doctor if you think your child is not growing at a normal rate while using this medication over a long treatment period.

How should I use Cyclocort (amcinonide topical)?

Use this medication exactly as directed on the label, or as it has been prescribed by your doctor. Do not use the medication in larger amounts or for longer than recommended. Topical steroid medicine can be absorbed through the skin, which may cause steroid side effects throughout the body.

Wash your hands before and after using amcinonide topical, unless you are using the medication to treat the skin on your hands.

Apply a small amount to the affected area and rub it gently into the skin. Do not use this medication over a large area of skin.

Do not cover treated skin areas with a bandage or other covering unless your doctor has told you to. If you are treating the diaper area of a baby, do not use plastic pants or tight-fitting diapers. Covering the skin that is treated with amcinonide topical can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects. Follow your doctor's instructions. Contact your doctor if your condition does not improve within 2 weeks of using this medicine, or if you develop signs of a bacterial, fungal, or viral skin infection. It is important to use amcinonide topical regularly to get the most benefit.

To be sure this medication is not causing harmful effects with long-term use, you may need blood tests. Do not miss any scheduled appointments.

Store amcinonide topical at room temperature away from moisture and heat. Keep from freezing.

What happens if I miss a dose?

Use the medication as soon as you remember. If it is almost time for the next dose, skip the missed dose and use the medicine at the next regularly scheduled time. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.

An overdose of amcinonide is not expected to produce life-threatening symptoms. However, long-term use of high steroid doses can lead to symptoms such as thinning skin, easy bruising, changes in the shape or location of body fat (especially in your face, neck, back, and waist), increased acne or facial hair, menstrual problems, impotence, or loss of interest in sex.

What should I avoid while using Cyclocort (amcinonide topical)?

Amcinonide topical should not be used to treat any skin condition your doctor has not prescribed it for.

Avoid getting this medication in your eyes. If contact does occur, rinse with water. Do not use amcinonide topical on broken or infected skin. Also avoid using this medication in open wounds.

Cyclocort (amcinonide topical) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have severe irritation of any treated skin, or if you show signs of absorbing amcinonide topical through your skin, such as:

• 
  

  blurred vision, or seeing halos around lights;

  
  


• 
  

  mood changes;

  
  


• 
  

  sleep problems (insomnia);

  
  


• 
  

  weight gain, puffiness in your face; or

  
  


• 
  

  muscle weakness, feeling tired.

  
  

Less serious side effects may include:

• 
  

  mild skin rash, itching, burning, redness, or dryness;

  
  


• 
  

  thinning or softening of your skin;

  
  


• 
  

  skin rash or irritation around your mouth;

  
  


• 
  

  swollen hair follicles;

  
  


• 
  

  changes in color of treated skin;

  
  


• 
  

  blisters, pimples, or crusting of treated skin; or

  
  


• 
  

  stretch marks.

  
  

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Cyclocort (amcinonide topical)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied amcinonide topical. But many drugs can interact with each other. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

More Cyclocort resources

• Cyclocort Side Effects (in more detail)
• Cyclocort Use in Pregnancy & Breastfeeding
• Cyclocort Drug Interactions
• Cyclocort Support Group
• 0 Reviews for Cyclocort - Add your own review/rating

• Cyclocort Advanced Consumer (Micromedex) - Includes Dosage Information


• Cyclocort Cream MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Cyclocort with other medications

• Atopic Dermatitis
• Dermatitis
• Eczema
• Psoriasis

Where can I get more information?

• Your pharmacist can provide more information about amcinonide topical.

See also: Cyclocort side effects (in more detail)

Hemochromatosis Medications

There are currently no drugs listed for "Hemochromatosis".

Definition of Hemochromatosis: Hemochromatosis is an inherited disease that occurs when the body absorbs too much iron.

Learn more about Hemochromatosis

Medical Encyclopedia:

• Hemochromatosis

Harvard Health Guide:

• Symptoms and treatment for Hemochromatosis

Drug List:

Cyproheptadine Hydrochloride

Class: First Generation Antihistamines
ATC Class: R06AX02
VA Class: AH107
Chemical Name: 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride
Molecular Formula: C₂₁H₂₁N•HCl
CAS Number: 41354-29-4

Special Alerts:

[Posted 10/09/2008] FDA notified healthcare professionals and consumers that the Consumer Healthcare Products Association (CHPA) is voluntarily modifying the product labels for consumers of over the counter (OTC) cough and cold medicines to state “do not use” in children under 4 years of age. FDA supports CHPA members to help prevent and reduce misuse and to better inform consumers about the safe and effective use of these products for children. FDA continues to assess the safety and efficacy of these products and to revise its OTC list of approved ingredients and amounts for these medicines. Parents and care givers should adhere to the dosage instructions and warnings on the label that accompanies OTC cough and cold medications before giving the product to children, and should consult their healthcare professionals if they have any questions or concerns. For more information visit the FDA website at: and .

Introduction

First generation antihistamine; serotonin antagonist;^{5 6 27 40 43 50 51} structurally and pharmacologically related to azatadine.^{1 5}

Uses for Cyproheptadine Hydrochloride

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Allergic Conditions

Treatment of cold urticaria.^{5 11 12 13 74 75}

Symptomatic relief of perennial (nonseasonal) and seasonal (e.g., hay fever) allergic rhinitis.^{74 75 c}

Management of nonallergic (vasomotor) rhinitis.^{74 75}

Management of allergic conjunctivitis caused by foods or inhaled allergens.^{74 75 c}

Management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.^{74 75}

Treatment of dermatographism.^{74 75 c}

Amelioration of allergic reactions to blood or plasma.^{74 75 c}

Adjunct to epinephrine and other standard measures for management of anaphylactic reactions after acute manifestations have been controlled.^{74 75}

Cushing’s Syndrome

Has been effective in some patients for the treatment of Cushing’s syndrome† secondary to pituitary disorders;^{14 15 16 17 18 19 20 21 48 52 53 63} however, in most patients, other therapy (e.g., surgery, radiation therapy) is preferred.^{21 39 48}

Sexual Dysfunction

Has been effective for the management of inhibited male or female orgasm† (anorgasmy) induced by tricyclic antidepressants,^{55 57 58 66} MAO inhibitors,^{54 56} fluoxetine,⁶⁸ or antipsychotic agents.⁵⁶ However, consider the potential for interactions between these drugs and cyproheptadine.^{5 66} (See Interactions.)

Anorexia Nervosa

Has been shown to stimulate appetite and weight gain in children^{32 33} and adults;^{34 35 36} however, few indications for clinical use.⁴⁰ May be of some value in the treatment of anorexia nervosa†;^{37 38 41 46 47 59 60} may be more effective in nonbulimic patients than in those who are bulimic.⁵⁹

Headache

Reportedly has been effective in some patients for the management of vascular headaches† (e.g., migraine).^{30 31 43 44 71} Efficacy for prophylaxis of migraine not established in randomized controlled studies, but some experts consider the drug to be effective based on consensus and clinical experience.⁷¹

Cyproheptadine Hydrochloride Dosage and Administration

Administration

Oral Administration

Administer orally as tablets or oral solution.^{74 75}

Dosage

Available as cyproheptadine hydrochloride; dosage expressed in terms of the salt.^{74 75}

Pediatric Patients

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Allergic Conditions

Oral

Children 2–6 years of age: Usual dosage is 2 mg 2 or 3 times daily; adjust as needed based on the size and response of the patient, up to maximum of 12 mg daily.^{5 74 75} (See Pediatric Use under Cautions.)

Children 7–14 years of age: Usual dosage is 4 mg 2 or 3 times daily; adjust as needed based on the size and response of the patient, up to maximum of 16 mg daily.^{5 74 75}

Adolescents ≥15 years of age: Initially, 4 mg 3 times daily; adjust based on the size and response of the patient, up to 0.5 mg/kg daily.^{74 75} Dosage range: 4–20 mg daily; most patients require 12–16 mg daily.^{74 75}

Alternatively, children ≥2 years of age may receive 0.25 mg/kg or 8 mg/m² daily in divided doses.^{5 74 75}

Anorexia Nervosa†

Oral

Adolescents ≥13 years of age: Dosage of 2 mg 4 times daily, increased gradually over a 3-week period to up to 8 mg 4 times daily, has been used.^{38 46 47 59}

Adults

Allergic Conditions

Oral

Initially, 4 mg 3 times daily; adjust as needed based on the size and response of the patient, up to 0.5 mg/kg daily.^{5 74 75}

Dosage range: 4–20 mg daily; most patients require 12–16 mg daily.^{5 74 75} Some patients may require up to 32 mg daily.^{5 74 75}

Cushing’s Syndrome†

Oral

Initially, 8 mg daily in divided doses; gradually increase dosage to up to 24 mg daily in divided doses.^{14 17 18 21 48 52}

Anorexia Nervosa†

Oral

Dosage of 2 mg 4 times daily, increased gradually over a 3-week period to up to 8 mg 4 times daily, has been used.^{38 46 47 59}

Prescribing Limits

Pediatric Patients

Allergic Conditions

Oral

Children 2–6 years of age: Maximum 12 mg daily.^{74 75}

Children 7–14 years of age: Maximum 16 mg daily.^{74 75}

Adolescents ≥15 years of age: Maximum 0.5 mg/kg daily.^{74 75}

Anorexia Nervosa†

Oral

Adolescents ≥13 years of age: Maximum 32 mg daily.^{38 46 47 59}

Adults

Allergic Conditions

Oral

Maximum 0.5 mg/kg daily.^{74 75}

Cushing’s Syndrome†

Oral

Maximum 24 mg daily.^{14 17 18 21 48 52}

Anorexia Nervosa†

Oral

Maximum 32 mg daily.^{38 46 47 59}

Special Populations

Geriatric Patients

Select dosage with caution, starting at the lower end of the usual dosage range.^{5 74} (See Geriatric Use under Cautions.)

Cautions for Cyproheptadine Hydrochloride

Contraindications

• 
  

  Neonates and premature infants.^{74 75}

  
  


• 
  

  Women who are breast-feeding.^{74 75} (See Lactation and also Pediatric Use under Cautions.)

  
  


• 
  

  Known hypersensitivity to cyproheptadine or other drugs with similar chemical structures.^{74 75}

  
  


• 
  

  Patients receiving MAO inhibitor therapy.^{74 75} (See Interactions.)

  
  


• 
  

  Known history of angle-closure glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, or pyloroduodenal obstruction.^{74 75}

  
  


• 
  

  Debilitated geriatric patients.^{74 75}

  
  

Warnings/Precautions

Warnings

CNS Effects

Risk of marked drowsiness.^{74 75 c} Caution required when performing hazardous activities requiring mental alertness and motor coordination (e.g., driving a motor vehicle, operating machinery).^{74 75 c}

Possible excitability (especially in children).^{74 75 c} (See Pediatric Use under Cautions.)

Concurrent use of other CNS depressants may have additive CNS depressant effects.^{74 75 c} (See Interactions.)

General Precautions

Concomitant Diseases

Because of anticholinergic effects, use with caution in patients with increased intraocular pressure, active or history of respiratory disease (e.g., bronchial asthma), hyperthyroidism, or cardiovascular disease (e.g., hypertension).^{74 75 c} (See Contraindications.) Use of antihistamines generally not recommended in asthmatics who previously experienced a serious antihistamine-induced adverse bronchopulmonary effect.

Specific Populations

Pregnancy

Category B.^{74 75}

Lactation

Not known whether cyproheptadine is distributed into milk.^{5 74}

Because of potential for serious adverse effects in nursing infants, discontinue nursing or the drug.^{5 74 75} (See Pediatric Use under Cautions.)

Pediatric Use

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Contraindicated in neonates and premature infants.^{74 75}

Safety and efficacy of cyproheptadine not established in children <2 years of age.^{74 75}

Risk of overdosage and toxicity (including death) in children <2 years of age receiving OTC preparations containing antihistamines, cough suppressants, expectorants, and nasal decongestants alone or in combination for relief of symptoms of upper respiratory tract infection.^{72 73} Limited evidence of efficacy for these preparations in this age group; appropriate dosages not established.⁷² Therefore, FDA recommended not to use such preparations in children <2 years of age; safety and efficacy in older children currently under evaluation. Because children 2–3 years of age also are at increased risk of overdosage and toxicity, some manufacturers of oral nonprescription cough and cold preparations recently agreed to voluntarily revise the product labeling to state that such preparations should not be used in children <4 years of age. During the transition period, some preparations on pharmacy shelves will have the new recommendation (“do not use in children <4 years of age”), while others will have the previous recommendation (“do not use in children <2 years of age”). FDA recommends that parents and caregivers adhere to dosage instructions and warnings on the product labeling that accompanies the preparation and consult a clinician about any concerns. Clinicians should ask caregivers about use of OTC cough/cold preparations to avoid overdosage.

Cyproheptadine overdosage, particularly in infants and young children, may produce hallucinations, CNS depression, seizures, respiratory and cardiac arrest, and death.^{74 75}

Possible paradoxical excitement (e.g., restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures), especially in young children.^{74 75 c} Central anticholinergic syndrome (e.g., hallucinations, agitation, confusion) has occurred.

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; clinical experience has not revealed age-related differences.^{5 74} Select dosage with caution (usually starting at low end of dosage range) because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.^{5 74}

Possible increased risk of dizziness, sedation, and hypotension in geriatric patients.^{74 75}

Contraindicated in debilitated geriatric patients.^{74 75}

Common Adverse Effects

Sedation,^{74 75} sleepiness (often transient),^{74 75} dizziness,^{74 75} disturbed coordination,^{74 75} restlessness,^{74 75} excitation.^{74 75}

Interactions for Cyproheptadine Hydrochloride

Specific Drugs and Laboratory Tests

Drug	Interaction	Comments
CNS depressants (e.g., alcohol, hypnotics, sedatives, tranquilizers)	Possible additive CNS depression74 75 c	Use caution to avoid overdosage;c advise patient to avoid alcohol
Fluoxetine	Reversal of fluoxetine's antidepressant effects reported in limited number of patients, possibly due to inhibition of fluoxetine's serotonergic effects69 70
MAO inhibitors	MAO inhibitors prolong and intensify anticholinergic effects of antihistamines74 75 c
Test, antigen or histamine	Inhalation-challenge testing with histamine or antigen: Possible suppression of test response Antigen skin testing: Possible suppression of wheal and flare reactions

Cyproheptadine Hydrochloride Pharmacokinetics

Absorption

Bioavailability

Well absorbed following oral administration.^{1 7}

Distribution

Extent

Distribution into human body tissues and fluids has not been characterized.⁷

Elimination

Metabolism

Appears to be almost completely metabolized,^{7 8 9 10} principally to the quaternary ammonium glucuronide conjugate.^{8 9 10}

Elimination Route

Principally in urine, as conjugates; ^{7 8 9 10} also in feces following oral administration.^{5 7 74 75}

Special Populations

Elimination is reduced in renal insufficiency.^{5 74 75}

Stability

Storage

Oral

Solution

15–30°C.⁷⁵

Tablets

Tightly closed container at 15–30°C.⁷⁴

ActionsActions

• 
  

  Has potent antihistaminic and serotonin antagonist properties; also has anticholinergic and sedative effects^{5 6 40 50 51} and reportedly has calcium-channel blocking activity.⁴²

  
  

Advice to Patients

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

• 
  

  Risk of drowsiness;^{74 75 c} avoid alcohol and use caution when engaging in activities requiring mental alertness and motor coordination (e.g., driving a motor vehicle, operating machinery).^{74 75 c}

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.^{74 75}

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.^{74 75}

  
  


• 
  

  Importance of informing patients of other important precautionary information.^{74 75} (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Cyproheptadine Hydrochloride

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Solution	2 mg/5 mL*	Cyproheptadine Hydrochloride Syrup
	Tablets	4 mg*	Cyproheptadine Hydrochloride Tablets

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Cyproheptadine HCl 2MG/5ML Syrup (ACTAVIS MID ATLANTIC): 120/$18.99 or 360/$38.97

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions November 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Schering. Optimine prescribing information. In: Huff BB, ed. Physicians’ desk reference. 38th ed. Oradell, NJ: Medical Economics Company Inc; 1984:1795-7.

2. The United States pharmacopeia, 21st rev, and The national formulary, 16th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1984:267, 1450, 1484.

3. Hoffman JP (Merck, Sharp and Dohme): Personal communication; 1978 May 15.

4. United States Pharmacopeia Dispensing Information (USP DI). Vol I. Drug information for the health care provider. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1983:142.

5. Merck & Co. Periactin (cyproheptadine) tablets and syrup prescribing information. West Point, PA; 1999 Sept.

6. Stone CA, Wenger HC, Ludden CT et al. Antiserotonin-antihistaminic properties of cyproheptadine. J Pharmacol Exp Ther. 1961; 131:73-84.

7. Hintze KL, Wold JS, Fischer LJ. Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite. Drug Metab Dispos. 1975; 3:1-9. [IDIS 50715] [PubMed 234828]

8. Porter CC, Arison BH, Gruber VF et al. Human metabolism of cyproheptadine. Drug Metab Dispos. 1975; 3:189-97. [IDIS 52901] [PubMed 238818]

9. Kennedy KA, Halmi KA, Fischer LJ. Urinary excretion of a quaternary ammonium glucuronide metabolite of cyproheptadine in humans undergoing chronic drug therapy. Life Sci. 1977; 21:1813-20. [PubMed 604709]

10. Fischer LJ, Thies RL, Charkowski D et al. Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees, and humans. Drug Metab Dispos. 1980; 8:422-4. [IDIS 128861] [PubMed 6109610]

11. Wanderer AA, St. Pierre JP, Ellis EF. Primary acquired cold urticaria: double-blind comparative study of treatment with cyproheptadine, chlorpheniramine, and placebo. Arch Dermatol. 1977; 113:1375-7. [IDIS 89712] [PubMed 334082]

12. Sigler RW, Evans R III, Horakova Z et al. The role of cyproheptadine in the treatment of cold urticaria. J Allergy Clin Immunol. 1980; 65:309-12. [IDIS 112895] [PubMed 6102102]

13. Buckley RH, Mathews KP. Common “allergic” skin diseases. JAMA. 1982; 248:2611-22. [IDIS 160684] [PubMed 7143623]

14. Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing’s disease. N Engl J Med. 1975; 293:893-6. [IDIS 55425] [PubMed 1177986]

15. Krieger DT. Cyproheptadine for pituitary disorders. N Engl J Med. 1976; 295:394-5. [PubMed 934231]

16. Grant DB, Atherden SM. Cushing’s disease presenting with growth failure: clinical remission during cyproheptadine therapy. Arch Dis Child. 1979; 54:466-8. [IDIS 99588] [PubMed 475431]

17. Hsu TH, Gann DS, Tsan KW et al. Cyproheptadine in the control of Cushing’s disease. Johns Hopkins Med J. 1981; 149:77-83. [IDIS 137249] [PubMed 6265685]

18. Jimenez-Alonso J, Munoz-Avila J, Jaimez L et al. Cyproheptadine-induced remission of Cushing’s disease due to pituitary basophil adenoma. Drug Intell Clin Pharm. 1982; 16:962-5. [IDIS 161163] [PubMed 6295736]

19. Griffith DN, Rose EJ. Pregnancy after cyproheptadine treatment for Cushing’s disease. N Engl J Med. 1981; 305:893-4. [IDIS 137895] [PubMed 7278892]

20. Kasperlik-Zaluska A, Migdalska B, Hartwig W et al. Two pregnancies in a woman with Cushing’s syndrome treated with cyproheptadine: case report. Br J Obstet Gynaecol. 1980; 87:1171-3. [PubMed 7437385]

21. Gold EM. The Cushing syndromes: changing views of diagnosis and treatment. Ann Intern Med. 1979; 90:829-44. [IDIS 95709] [PubMed 219743]

22. Hartwig W, Kasperlik-Zaluska A, Wilczynska J et al. Cyproheptadine for pituitary disorders. N Engl J Med. 1976; 295:394. [PubMed 934231]

23. Krieger DT, Condon EM. Cyproheptadine treatment of Nelson’s syndrome: restoration of plasma ACTH circadian periodicity and reversal of response to TRF. J Clin Endocrinol Metab. 1978; 46:349-52. [IDIS 101716] [PubMed 220278]

24. Aronin N, Krieger DT. Sustained remission of Nelson’s syndrome after stopping cyproheptadine treatment. N Engl J Med. 1980; 302:453-5. [IDIS 110686] [PubMed 6243392]

25. Hsu TH. Management of virilizing congenital adrenal hyperplasia with cyproheptadine. Ann Intern Med. 1980; 92:628-30. [IDIS 113155] [PubMed 7387003]

26. Wortsman J, Soler NG, Hirschowitz J. Cyproheptadine in the management of the galactorrhea-amenorrhea syndrome. Ann Intern Med. 1979; 90:923-5. [IDIS 96572] [PubMed 571691]

27. Vroom FQ, Brown RE, Dempsey H et al. Studies on several possible antiserotonin compounds in a patient with the functioning carcinoid syndrome. Ann Intern Med. 1962; 56:941-5. [PubMed 13926919]

28. Berry EM, Maunder C, Wilson M. Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut. 1974; 15:34-8. [IDIS 45837] [PubMed 4274414]

29. Harris AL, Smith IE. Regression of carcinoid tumour with cyproheptadine. BMJ. 1982; 285:475. [IDIS 155028] [PubMed 6809131]

30. Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Neurosurg Psychiatry. 1964; 27:463-9. [PubMed 14213477]

31. Lance JW, Curran DA, Anthony M. Investigations into the mechanism and treatment of chronic headache. Med J Aust. 1965; 2:909-14. [PubMed 5322372]

32. Lavenstein AF, Decaney EP, Lasagna L et al. Effect of cyproheptadine on asthmatic children. JAMA. 1962; 180:912-6. [PubMed 14462919]

33. Bergen SS. Appetite stimulating properties of cyproheptadine. Am J Dis Child. 1964; 108:270-3. [PubMed 14168064]

34. Noble RE. Effect of cyproheptadine on appetite and weight gain in adults. JAMA. 1969; 209:2054-5. [PubMed 4897366]

35. Silverstone T, Schuyler D. The effect of cyproheptadine on hunger, calorie intake, and body weight in man. Psychopharmacologia. 1975; 40:335-40. [PubMed 1096217]

36. Pawlowski GJ. Cyproheptadine: weight-gain and appetite stimulation in essential anorexic adults. Curr Ther Res Clin Exp. 1975; 18:673-8. [PubMed 812645]

37. Goldberg SC, Halmi KA, Eckert ED. Cyproheptadine in anorexia nervosa. Br J Psychiatry. 1979; 134:67-70. [PubMed 367480]

38. Halmi KA, Eckert E, Falk JR. Cyproheptadine for anorexia nerovsa. Lancet. 1982; 1:1357-8. [IDIS 151434] [PubMed 6123657]

39. Vaughan GM, Taylor TJ. Cushing’s syndrome. In: Conn HF, ed. Current therapy: latest approved methods of treatment for the practicing physician, 1983. Philadelphia: WB Saunders Company; 1983:472-7.

40. Anon. Cyproheptadine. Lancet. 1978; 1:367-8.

41. Goldberg SC, Eckert ED, Halmi KA et al. Effects of cyproheptadine on symptoms and attitudes in anorexia nervosa. Arch Gen Psychiatry. 1980; 37:1083. [IDIS 123856] [PubMed 7416909]

42. Peroutka SJ, Allen GS. The calcium antagonist properties of cyproheptadine: implications for antimigraine action. Neurology. 1984; 34:304-9. [PubMed 6538269]

43. Lance JW, Anthony M, Somerville B. Comparative trial of serotonin antagonists in the management of migraine. Br Med J. 1970; 1:327-30. [PubMed 4906701]

44. Bille B, Ludvigsson J, Sanner G. Prophylaxis of migraine in children. Headache. 1977; 17:61-3. [PubMed 324951]

45. Greenberger P, Patterson R. Safety of therapy for allergic symptoms during pregnancy. Ann Intern Med. 1978; 89:234-7. [PubMed 28058]

46. Falk JR, Halmi KA, Tyron WW. Activity measures in anorexia nervosa. Arch Gen Psychiatry. 1985; 42:811-4. [PubMed 4015326]

47. Herzog DB, Copeland PM. Eating disorders. N Engl J Med. 1985; 313:295-303. [IDIS 202663] [PubMed 2861566]

48. Burch WM. Cushing’s disease: a review. Arch Intern Med. 1985; 145:1106-11. [IDIS 200607] [PubMed 3923962]

49. Kaplowitz PB, Jennings S. Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. J Pediatr. 1987; 110:140-3. [IDIS 225707] [PubMed 3794875]

50. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:605-38.

51. Anthony M. Serotonin antagonists. Aust N Z J Med. 1984; 6:888-95.

52. Wiesen M, Ross F, Kreiger DT. Prolonged remission of a case of Cushing’s disease following cessation of cyproheptadine therapy. Acta Endocrinol (Copenh). 1983; 102:436-8. [PubMed 6829265]

53. Couch RM, Smail PJ, Dean HJ et al. Prolonged remission of Cushing disease after treatment with cyproheptadine. J Pediatr. 1984; 104:906-8. [IDIS 186484] [PubMed 6327962]

54. DeCastro RM. Reversal of MAOI-induced anorgasmia with cyproheptadine. Am J Psychiatry. 1985; 142:783. [IDIS 200783] [PubMed 4039897]

55. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry. 1986; 148:217-8. [PubMed 3697592]

56. Jeffries JJ. Cyproheptadine and drug-induced anorgasmia. Can J Psychiatry. 1987; 32:79. [PubMed 2880654]

57. Sovner R. Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. J Clin Psychopharmacol. 1984; 4:169. [PubMed 6736278]

58. Steele TE, Howell EF. Cyproheptadine for imipramine-induced anorgasmia. J Clin Psychopharmacol. 1986; 6:326-7. [IDIS 221973] [PubMed 3771824]

59. Halmi KA, Eckert E, LaDu TJ et al. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986; 43:177-81. [IDIS 212256] [PubMed 3511877]

60. Johnson C, Stuckey M, Mitchell J. Psychopharmacological treatment of anorexia nervosa and bulimia: review and synthesis. J Nerv Ment Dis. 1983; 171:524-34. [PubMed 6310046]

61. Mylan Pharmaceuticals Inc. Cyproheptadine hydrochloride tablets, USP prescribing information. Morgantown, WV; 1985 Feb.

62. Merck Sharp & Dohme. Periactin prescribing information. In: Huff BB, ed. Physicians’ desk reference. 41st ed. Oradell, NJ: Medical Economics Company Inc; 1987 (Suppl A):A43.

63. Khir ASM, How J, Bewsher PD. Successful pregnancy after cyproheptadine treatment for Cushing’s disease. Eur J Obstet Gynecol Reprod Biol. 1982; 13:343-7. [PubMed 7128894]

64. Padfield NL. Carcinoid syndrome: comparison of pretreatment regimes in the same patient. Ann R Coll Surg Engl. 1987; 69:16-7. [PubMed 2952043]

65. Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome: a selective review of chemotherapy and hormonal therapy. Am J Med. 1986; 81(Suppl 6B):49-55. [IDIS 224868] [PubMed 2432781]

66. Pontius EB. Case report of an anticholinergic crisis associated with cyproheptadine treatment of desipramine-induced anorgasmia. J Clin Psychopharmacol. 1988; 8:230-1. [IDIS 242985] [PubMed 3379154]

67. Merck Sharp & Dohme. Periactin tablets and syrup prescribing information. In: Physician’s desk reference. 52nd ed. Montvale, NJ: Medical Economics Company Inc; 1998:1720-1.

68. McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry. 1990; 51:383-4. [IDIS 272903] [PubMed 2211550]

69. Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry. 1991; 52:163-4. [IDIS 281251] [PubMed 2016249]

70. Fluoxetine/cyproheptadine. In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1992(Jan):344c.

71. Ramadan NM, Silberstein SD, Freitag F et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN; 2001. From the American Academy of Neurology web site: ().

72. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. [PubMed 17218934]

73. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website ().

74. Corepharma LLC. Cyproheptadine hydrochloride (Cyproheptadine Hydrochloride) tablet prescribing information. Middlesex, NJ; 2006 Jun.

75. Alpharma USPD. Cyproheptadine hydrochloride oral solution prescribing information. Baltimore, MD; 2005 Jun.

c. AHFS drug information 2007. McEvoy GK, ed. Antihistamines general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1-8.

More Cyproheptadine Hydrochloride resources

• Cyproheptadine Hydrochloride Side Effects (in more detail)
• Cyproheptadine Hydrochloride Use in Pregnancy & Breastfeeding
• Drug Images
• Cyproheptadine Hydrochloride Drug Interactions
• Cyproheptadine Hydrochloride Support Group
• 20 Reviews for Cyproheptadine Hydrochloride - Add your own review/rating

• Cyproheptadine Prescribing Information (FDA)


• cyproheptadine Concise Consumer Information (Cerner Multum)


• Cyproheptadine MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Cyproheptadine Hydrochloride with other medications

• Allergic Reactions
• Anorexia
• Anorexia Nervosa
• Cluster Headaches
• Cushing's Syndrome
• Failure to Thrive
• Hay Fever
• Migraine
• Pruritus
• Sexual Dysfunction, SSRI Induced
• Urticaria

Sulfacetamide/Sulfur Cleansing Cloths

Pronunciation: sul-fa-SEE-ta-mide/SULL-fer
Generic Name: Sulfacetamide/Sulfur
Brand Name: Plexion Cleansing Cloths

Sulfacetamide/Sulfur Cleansing Cloths are used for:

Treating acne, rosacea, and seborrhea. It may also be used for other conditions as determined by your doctor.

Sulfacetamide/Sulfur Cleansing Cloths are a sulfonamide antibiotic and keratolytic. It works by killing bacteria and shedding the top layer of skin to help treat acne.

Do NOT use Sulfacetamide/Sulfur Cleansing Cloths if:

• you are allergic to any ingredient in Sulfacetamide/Sulfur Cleansing Cloths


• you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) to any other sulfonamide medicine, such as acetazolamide, celecoxib, certain diuretics (eg, hydrochlorothiazide), glyburide, probenecid, sulfamethoxazole, valdecoxib, or zonisamide


• you have kidney disease

Contact your doctor or health care provider right away if any of these apply to you.

Before using Sulfacetamide/Sulfur Cleansing Cloths:

Some medical conditions may interact with Sulfacetamide/Sulfur Cleansing Cloths. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have eczema or a history of lupus

Some MEDICINES MAY INTERACT with Sulfacetamide/Sulfur Cleansing Cloths. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Silver-containing products (eg, silver sulfadiazine) because they may decrease Sulfacetamide/Sulfur Cleansing Cloths's effectiveness


• Methenamine because the side effects of Sulfacetamide/Sulfur Cleansing Cloths may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Sulfacetamide/Sulfur Cleansing Cloths may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Sulfacetamide/Sulfur Cleansing Cloths:

Use Sulfacetamide/Sulfur Cleansing Cloths as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Sulfacetamide/Sulfur Cleansing Cloths are for use on the skin only. Sulfacetamide/Sulfur Cleansing Cloths may stain clothing and the skin if too much is used.


• Wash your hands before and immediately after using Sulfacetamide/Sulfur Cleansing Cloths. Wet your face with water. Wet the cloth with a little water and work into a full lather. Cleanse face with cloth for 10 to 20 seconds, avoiding the eyes. Rinse thoroughly and pat dry.


• Throw away the cloth after use. Do not flush it down the toilet.


• To clear up your infection completely, use Sulfacetamide/Sulfur Cleansing Cloths for the full course of treatment. Keep using it even if you feel better in a few days.


• Sulfacetamide/Sulfur Cleansing Cloths works best if it is used at the same time each day.


• Continue to use Sulfacetamide/Sulfur Cleansing Cloths even if you feel well. Do not miss any doses.


• If you miss a dose of Sulfacetamide/Sulfur Cleansing Cloths, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Sulfacetamide/Sulfur Cleansing Cloths.

Important safety information:

• Avoid getting Sulfacetamide/Sulfur Cleansing Cloths in your eyes, eyelids, nose, or mouth. If you get Sulfacetamide/Sulfur Cleansing Cloths in your eyes, rinse immediately with cool tap water.


• Talk with your doctor before you use any other medicines or cleansers on your skin.


• Do not apply Sulfacetamide/Sulfur Cleansing Cloths to open wounds or to damaged or burned skin without first checking with your doctor.


• If you use topical products too often, your condition may become worse.


• Sulfacetamide/Sulfur Cleansing Cloths only works against bacteria; it does not treat viral infections.


• Be sure to use Sulfacetamide/Sulfur Cleansing Cloths for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.


• Long-term or repeated use of Sulfacetamide/Sulfur Cleansing Cloths may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.


• Sulfacetamide/Sulfur Cleansing Cloths should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Sulfacetamide/Sulfur Cleansing Cloths while you are pregnant. It is not known if Sulfacetamide/Sulfur Cleansing Cloths are found in breast milk after topical use. If you are or will be breast-feeding while you use Sulfacetamide/Sulfur Cleansing Cloths, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Sulfacetamide/Sulfur Cleansing Cloths:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Mild irritation, stinging, or burning of the skin.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fever; joint pain; red, swollen, scaling, or blistered skin; severe diarrhea; sores in the mouth; yellowing of the eyes or skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Sulfacetamide/Sulfur side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Sulfacetamide/Sulfur Cleansing Cloths may be harmful if swallowed. Symptoms of ingestion may include change in the amount of urine; nausea; vomiting.

Proper storage of Sulfacetamide/Sulfur Cleansing Cloths:

Store Sulfacetamide/Sulfur Cleansing Cloths at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Do not freeze. Keep Sulfacetamide/Sulfur Cleansing Cloths out of the reach of children and away from pets.

General information:

• If you have any questions about Sulfacetamide/Sulfur Cleansing Cloths, please talk with your doctor, pharmacist, or other health care provider.


• Sulfacetamide/Sulfur Cleansing Cloths are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Sulfacetamide/Sulfur Cleansing Cloths. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Sulfacetamide/Sulfur resources

• Sulfacetamide/Sulfur Side Effects (in more detail)
• Sulfacetamide/Sulfur Use in Pregnancy & Breastfeeding
• Sulfacetamide/Sulfur Drug Interactions
• Sulfacetamide/Sulfur Support Group
• 18 Reviews for Sulfacetamide/Sulfur - Add your own review/rating

Compare Sulfacetamide/Sulfur with other medications

• Acne
• Rosacea
• Seborrheic Dermatitis

Methylphenidate Extended-Release Tablets

Pronunciation: METH-il-FEN-i-date
Generic Name: Methylphenidate
Brand Name: Concerta

Use Methylphenidate Extended-Release Tablets with caution if you have a history of emotional problems or alcohol or substance abuse. Abuse of Methylphenidate Extended-Release Tablets may cause it to not work as well. Abuse may also lead to addiction and severe mental changes. Do not suddenly stop using Methylphenidate Extended-Release Tablets. Depression and other mental problems may occur. Your doctor should slowly lower your dose over a period of time if you need to stop using it.

Methylphenidate Extended-Release Tablets are used for:

Treating attention deficit hyperactivity disorder (ADHD). It may also be used for other conditions as determined by your doctor.

Methylphenidate Extended-Release Tablets are a central nervous system stimulant. Exactly how it works is not known.

Do NOT use Methylphenidate Extended-Release Tablets if:

• you are allergic to any ingredient in Methylphenidate Extended-Release Tablets


• you have severe anxiety, agitation, or tension


• you have glaucoma


• you have motor tics (involuntary movements), Tourette syndrome, or a family history of Tourette syndrome


• you have serious heart problems (eg, heart defect, irregular heartbeat)


• you are not able to swallow the tablet whole


• you are taking a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) or have taken an MAOI within the past 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Methylphenidate Extended-Release Tablets:

Some medical conditions may interact with Methylphenidate Extended-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of high blood pressure, heart problems (eg, heart failure, fast or irregular heartbeat), or a recent heart attack, or if a family member has a history of irregular heartbeat or sudden death


• if you have a history of seizures or abnormal electroencephalograms (EEGs)


• if you have a history of overactive thyroid, chronic fatigue, cystic fibrosis, narrowing of the esophagus, or stomach or bowel problems (eg, blockage, inflammation, narrowing)


• if you have a history of mood or mental problems (eg, agitation, anxiety, bipolar disorder, depression, psychosis, tension), abnormal thoughts, hallucinations, suicidal thoughts or attempts, or alcohol or other substance abuse or dependence, or if a family member has a history of any of these problems

Some MEDICINES MAY INTERACT with Methylphenidate Extended-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• MAOIs (eg, phenelzine) because severe high blood pressure may occur


• Clonidine because serious side effects may occur


• Anticoagulants (eg, warfarin), certain anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine), or tricyclic antidepressants (eg, imipramine) because the risk of their side effects may be increased by Methylphenidate Extended-Release Tablets


• Medicines for high blood pressure (eg, guanethidine, metoprolol) because their effectiveness may be decreased by Methylphenidate Extended-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Methylphenidate Extended-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Methylphenidate Extended-Release Tablets:

Use Methylphenidate Extended-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Methylphenidate Extended-Release Tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Methylphenidate Extended-Release Tablets refilled.


• Take Methylphenidate Extended-Release Tablets by mouth in the morning with or without food.


• Swallow Methylphenidate Extended-Release Tablets whole. Do not break, crush, or chew before swallowing.


• Take Methylphenidate Extended-Release Tablets with a full glass of liquid (eg, water, milk, juice) (8 oz/240 mL).


• If you miss a dose of Methylphenidate Extended-Release Tablets, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Methylphenidate Extended-Release Tablets.

Important safety information:

• Methylphenidate Extended-Release Tablets may cause dizziness or drowsiness. These effects may be worse if you take it with alcohol or certain medicines. Use Methylphenidate Extended-Release Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do NOT take more than the recommended dose without checking with your doctor.


• If your symptoms do not get better within 1 month or if they get worse, check with your doctor.


• Serious effects, including heart attack, stroke, and sudden death, have occurred with the use of stimulant medicines in patients with heart defects or other serious heart problems. If you have a heart defect or another serious problem, talk with your doctor about other therapies to treat your condition.


• Tell your doctor or dentist that you take Methylphenidate Extended-Release Tablets before you receive any medical or dental care, emergency care, or surgery.


• You may notice the tablet shell in your stool. This is normal and not a cause for concern.


• Methylphenidate Extended-Release Tablets may be visible on abdominal x-rays. If you will be having an abdominal x-ray, be sure your doctor and lab personnel know you are taking Methylphenidate Extended-Release Tablets.


• Lab tests, including blood pressure, heart function, complete blood cell counts, and platelet counts, may be performed while you use Methylphenidate Extended-Release Tablets. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Methylphenidate Extended-Release Tablets may affect growth rate and weight gain in CHILDREN and teenagers in some cases. They may need regular growth and weight checks while they take Methylphenidate Extended-Release Tablets.


• Caution is advised when using Methylphenidate Extended-Release Tablets in CHILDREN; they may be more sensitive to its effects, especially loss of appetite, stomach pain, weight loss, trouble sleeping, and fast heartbeat.


• Methylphenidate Extended-Release Tablets should not be used in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Methylphenidate Extended-Release Tablets while you are pregnant. It is not known if Methylphenidate Extended-Release Tablets are found in breast milk. If you are or will be breast-feeding while you use Methylphenidate Extended-Release Tablets, check with your doctor. Discuss any possible risks to your baby.

When used for long periods of time or at high doses, Methylphenidate Extended-Release Tablets may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Methylphenidate Extended-Release Tablets stops working well. Do not take more than prescribed.

Some people who use Methylphenidate Extended-Release Tablets for a long time may develop a need to continue taking it. People who take high doses are also at risk. This is known as DEPENDENCE or addiction. Do not suddenly stop taking Methylphenidate Extended-Release Tablets. If you do, you may have WITHDRAWAL symptoms. These may include depression or other mental problems. If you need to stop Methylphenidate Extended-Release Tablets, your doctor will lower your dose over time.

Possible side effects of Methylphenidate Extended-Release Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Dizziness; drowsiness; dry mouth; headache; increased sweating; loss of appetite; nausea; nervousness; stomach pain; trouble sleeping; weight loss.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; joint pain; purple or brownish red spots on the skin); behavior changes (eg, aggression, hostility, restlessness); blurred vision or other vision problems; chest pain or discomfort; confusion; dark urine; fainting; fast or irregular heartbeat; fever, chills, or sore throat; hallucinations; mental or mood changes (eg, abnormal thoughts, agitation, anxiety, depression, irritability, panic attacks, persistent crying, unresponsiveness, unusual sadness); one-sided weakness; seizures; severe or persistent dizziness or headache; shortness of breath; slurred speech; suicidal thoughts or attempts; tremor; uncontrolled speech or muscle movements; yellowing of the eyes or skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Methylphenidate side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; dilated pupils; fast or irregular heartbeat; fever; flushing; hallucinations; loss of consciousness; muscle twitching; seizures; severe or persistent headache; tremors; unusual sweating; vomiting.

Proper storage of Methylphenidate Extended-Release Tablets:

Store Methylphenidate Extended-Release Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Methylphenidate Extended-Release Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Methylphenidate Extended-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Methylphenidate Extended-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Methylphenidate Extended-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Methylphenidate resources

• Methylphenidate Side Effects (in more detail)
• Methylphenidate Dosage
• Methylphenidate Use in Pregnancy & Breastfeeding
• Drug Images
• Methylphenidate Drug Interactions
• Methylphenidate Support Group
• 242 Reviews for Methylphenidate - Add your own review/rating

Compare Methylphenidate with other medications

• ADHD
• Depression
• Fatigue
• Narcolepsy
• Obesity
• Severe Mood Dysregulation